Treatment of staphylococcal infections with cyclic lipopeptides
- 1 March 2008
- journal article
- review article
- Published by Elsevier in Clinical Microbiology & Infection
- Vol. 14 (s2), 10-16
- https://doi.org/10.1111/j.1469-0691.2008.01921.x
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Antimicrobial ResistanceJAMA, 2007
- Invasive Methicillin-Resistant Staphylococcus aureus Infections in the United StatesJAMA, 2007
- Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001 05Journal of Antimicrobial Chemotherapy, 2007
- Increased Vancomycin MICs for Staphylococcus aureus Clinical Isolates from a University Hospital during a 5-Year PeriodJournal of Clinical Microbiology, 2006
- Microbiological Features of Vancomycin in the 21st Century: Minimum Inhibitory Concentration Creep, Bactericidal/Static Activity, and Applied Breakpoints to Predict Clinical Outcomes or Detect Resistant StrainsClinical Infectious Diseases, 2006
- The dearth of new antibiotic development: why we should be worried and what we can do about itThe Medical Journal of Australia, 2004
- Structural Transitions as Determinants of the Action of the Calcium-Dependent Antibiotic DaptomycinChemistry & Biology, 2004
- Correlation of Daptomycin Bactericidal Activity and Membrane Depolarization in Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2003
- Daptomycin: a novel lipopeptide antibioticClinical Microbiology Newsletter, 2002
- Daptomycin disrupts membrane potential in growing Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1991